Beyond the brain, reduced AIM2 levels correlate with prostate and colorectal cancer development (Dihlmann et al., 2014; Ponomareva et al., 2013), and increased AIM2 expression is associated with SLE (Javierre et al., 2010) and psoriasis (Dombrowski et al., 2011). Here, AIM2 is linked to systemic lupus erythematosus.